Serdemetan

Serdemetan (JNJ-26854165) is a potent anticancer agent with radiosensitizing activity. Serdemetan exhibits antiproliferative activity in various p53 wild-type tumor cells. Serdemetan also antagonizes the Mdm2-HIF1α axis leading to decreased levels of glycolytic enzymes[1][2][3].

Product Specifications

CAS Number

[881202-45-5]

Product Name Alternative

JNJ-26854165

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

Apoptosis; E1/E2/E3 Enzyme; MDM-2/p53

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Serdemetan.html

Purity

99.56

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

C1(NCCC2=CNC3=C2C=CC=C3)=CC=C(C=C1)NC4=CC=NC=C4

Molecular Formula

C21H20N4

Molecular Weight

328.41

Precautions

H315, H319, H320

References & Citations

[1]Chargari C, et, al. Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts. Cancer Lett. 2011 Dec 22;312 (2) :209-18. |[2]Lehman JA, et, al. Serdemetan antagonizes the Mdm2-HIF1α axis leading to decreased levels of glycolytic enzymes. PLoS One. 2013 Sep 6;8 (9) :e74741. |[3]Jones RJ, et, al. The novel anticancer agent JNJ-26854165 induces cell death through inhibition of cholesterol transport and degradation of ABCA1. J Pharmacol Exp Ther. 2013 Sep;346 (3) :381-92.